The Top 5 Biosimilar Articles for the Week of June 28

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 28, 2021.

Number 5: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a recommendation for the ranibizumab ophthalmology biosimilar candidate, Byooviz (SB11), to be approved for marketing authorization.

Number 4: Sizeable savings per patient with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) were anticipated by a Medicare savings model, investigators reported at this year's American Society of Clinical Oncology meeting.

Number 3: Authors of an opinion piece suggested that a "reliance" approach to biosimilar approval could lead to global standards for acceptance that cut down on wasted review time and obsolete clinical investigation.

Number 2: Investigators determined that converting at least 2 patients with metastatic breast cancer to a trastuzumab biosimilar (Ogivri) could generate savings enough to treat a third patient.

Number 1: Cigna said that it is rolling out a shared savings program that, among its signature features, will offer patients a $500 health services/products gift card for switching to a biosimilar.

To read all of these articles and more, visit centerforbiosimilars.com.